10-Q: Theravance Biopharma Soars on Royalty Sale, Strong Q2

Theravance Biopharma reported significant net income and cash flow for Q2 2025, driven by a $225 million sale of TRELEGY royalties to GSK and continued growth in YUPELRI sales.

Summary

• Theravance Biopharma reported a net income of $54.8 million for the three months ended June 30, 2025, a significant improvement from a net loss of $16.5 million in the prior year period.
• For the six months ended June 30, 2025, net income was $41.3 million, compared to a net loss of $28.2 million in the same period of 2024.
• Total revenues for the three months ended June 30, 2025, increased by 84% to $26.2 million, and for the six months, increased by 45% to $41.6 million, primarily due to a $7.5 million licensing revenue from YUPELRI's China approval.
• The company's cash, cash equivalents, and marketable securities significantly increased to $338.8 million as of June 30, 2025, up from $37.8 million at December 31, 2024.
• This substantial increase in cash and net income was largely driven by a $75.1 million net gain from the sale of TRELEGY royalties to GSK for $225.0 million in June 2025, and a $50.0 million milestone payment from Royalty Pharma in February 2025 related to 2024 TRELEGY global net sales.
• YUPELRI net sales (Theravance Biopharma's implied 35% share) increased by 22% to $23.2 million for the three months ended June 30, 2025, and by 14% to $43.6 million for the six months, benefiting from increased customer demand and improved net pricing.
• The Phase 3 CYPRESS study for ampreloxetine in Multiple System Atrophy (MSA) patients with symptomatic neurogenic orthostatic hypotension (nOH) is expected to complete final patient enrollment by late summer 2025, with top-line data anticipated approximately six months thereafter.
• The company has settled patent infringement litigation with several generic companies regarding YUPELRI, granting them royalty-free licenses to launch generic versions in the US on or after April 23, 2039, while litigation against two remaining generic companies is pending.

Sentiment

Score: 8

Explanation: The company's financial position has significantly improved due to a substantial one-time gain from the TRELEGY royalty sale, leading to a strong cash balance and net income. Operational revenue from YUPELRI is growing, and the key pipeline asset, Ampreloxetine, is progressing towards critical data readouts. Patent litigation settlements provide long-term market clarity for YUPELRI. While R&D and SG&A expenses increased, they are largely tied to pipeline advancement and one-time costs. The overall outlook is positive, with enhanced financial flexibility and clear strategic direction.

Positives

• Achieved significant net income of $54.8 million in Q2 2025 and $41.3 million in H1 2025, a substantial turnaround from prior year losses.
• Cash, cash equivalents, and marketable securities surged to $338.8 million, providing strong liquidity and funding for future operations for at least the next twelve months.
• Successfully monetized TRELEGY royalties, receiving $225.0 million from GSK and a $50.0 million milestone payment from Royalty Pharma, significantly boosting cash reserves.
• YUPELRI received regulatory approval in China from the NMPA, triggering a $7.5 million milestone payment from Viatris.
• YUPELRI's US net sales (implied 35% share) grew by 22% in Q2 2025 and 14% in H1 2025, driven by increased customer demand and improved net pricing.
• Ampreloxetine, a wholly-owned asset, is progressing well, with the Phase 3 CYPRESS study nearing final patient enrollment and top-line data expected within six months thereafter.
• Ampreloxetine was granted Orphan Drug Designation status by the FDA for symptomatic nOH in MSA patients, potentially streamlining its development and commercialization.
• Settled patent litigation with multiple generic companies for YUPELRI, securing long-term market exclusivity until April 23, 2039, for those agreements.

Negatives

• Research and development expenses increased by 16% to $21.9 million for the six months ended June 30, 2025, primarily due to the progression of the CYPRESS study and ampreloxetine regulatory activities.
• Selling, general and administrative expenses increased by 9% to $36.8 million for the six months ended June 30, 2025, partly due to one-time legal costs and pre-launch expenses for ampreloxetine.
• The company continues to incur costs and expenses associated with the commercialization of YUPELRI in the US and preparation for ampreloxetine's potential commercial launch.
• Despite recent profitability, the company has an accumulated deficit of $924.3 million as of June 30, 2025, reflecting historical losses.

Risks

• May never achieve or sustain profitability from operations, as recent net income was largely driven by a one-time gain.
• YUPELRI's acceptance by physicians, patients, and payors may not continue to grow, impacting future revenues.
• Delays in commencing or completing clinical studies for product candidates, or adverse results from studies, could harm the business.
• Product candidates may not be approved by regulatory authorities, preventing commercialization.
• Collaboration partners may not satisfy obligations or may terminate partnerships, affecting development and commercialization plans.
• Ongoing drug development efforts might not generate additional approvable drugs, despite current progress.
• The strategic review process may not result in an executed or consummated transaction or other strategic alternative, or its conclusion could adversely affect the business.
• Faces substantial competition from companies with more resources and experience, potentially leading to others commercializing products more successfully.
• Reliance on single sources of supply for product candidates and YUPELRI, posing risks if manufacturers cannot satisfy demand.
• Subject to extensive and ongoing regulation by the FDA and other authorities; failure to comply could result in penalties.
• Competition from companies seeking to market generic versions of approved products, such as YUPELRI, despite patent protection.
• Inability to enter into future collaboration arrangements or unsuccessful collaborations could hinder full development and commercialization of product candidates.
• Dependence on third parties for the conduct of non-clinical and clinical studies, with risks of non-compliance or delays.
• Adverse developments or perceived adverse developments with respect to TRELEGY could impact the receipt of remaining Milestone Payments.
• Loss of key management, sales, clinical development, or scientific personnel, or failure to attract and retain key employees, could impair business.
• Significant disruptions of information technology systems or security breaches could adversely affect business operations and result in harm.
• Global economic, political, and social conditions may harm the ability to do business, increase costs, and negatively affect stock price.
• Facility located near earthquake fault zones, and other catastrophic disasters could cause damage and disrupt operations.
• If sufficient capital is not available, operations may be curtailed, or rights to commercialize product candidates may need to be shared on unfavorable terms.
• May seek future financing through debt or equity, which could have an adverse effect on shareholders through dilution or senior claims.
• Potential to be treated as a US corporation for US federal income tax purposes, leading to substantial additional tax liability.
• Future tax reform, including changes in tax rates and imposition of new taxes, could impact results of operations and financial condition.
• Taxing authorities may challenge the company's structure and transfer pricing arrangements, leading to increased taxes or penalties.
• Risk of being classified as a Passive Foreign Investment Company (PFIC) for US federal income tax purposes in the future.
• Inability to maintain effective internal controls could adversely affect business, financial position, and results of operations.
• Efforts to protect intellectual property may be inadequate, leading to competitive disadvantages.
• Litigation to protect or defend intellectual property or third-party claims of infringement will divert resources and may delay drug development.
• Product liability and other lawsuits could divert resources, result in substantial liabilities, and reduce commercial potential.
• Failure to comply with data protection laws and regulations could lead to government enforcement actions, litigation, and adverse publicity.
• Changes in healthcare law and regulations, including government restrictions on pricing and reimbursement, may negatively impact the company.
• Failure to comply with reporting and payment obligations under government pricing programs could result in penalties and sanctions.
• Uncertainty regarding coverage and reimbursement status of new or current products could limit marketability and revenue generation.
• Relationships with customers and third-party payors are subject to anti-kickback, fraud and abuse, and other healthcare laws, risking sanctions.
• Business and operations involving hazardous and biological materials may result in environmental, health, and safety liabilities.
• Market price for shares has and may continue to fluctuate widely, resulting in substantial losses for purchasers.
• Activist shareholders could negatively impact the business and cause disruptions.
• Concentration of ownership limits the ability of other shareholders to influence corporate matters.
• Certain provisions in constitutional and other documents may discourage acquisition by a third party, limiting opportunities to sell shares at a premium.
• Shareholders may face difficulties in protecting their interests due to incorporation under Cayman Islands law.
• Uncertainty as to shareholders' ability to enforce certain foreign civil liabilities in the Cayman Islands.
• If securities or industry analysts cease coverage or publish inaccurate/unfavorable research, share price and trading volume could decline.
• Capital appreciation, if any, of ordinary shares may be the sole source of gain for the foreseeable future, as no cash dividends have been paid.
• As a smaller reporting company, compliance with reduced reporting requirements could make ordinary shares less attractive to investors.

Future Outlook

The company anticipates final patient enrollment in the Ampreloxetine Phase 3 CYPRESS study by late summer 2025, with top-line data expected approximately six months thereafter. It retains the right to receive up to $150.0 million in additional Milestone Payments from Royalty Pharma based on TRELEGY global net sales thresholds in 2025 and 2026. The company expects its current cash, cash equivalents, and marketable securities to be sufficient to fund operations for at least the next twelve months. The Strategic Review Committee continues to evaluate a range of alternatives to further enhance shareholder value.

Management Comments

• Our focus is to deliver medicines that make a difference in people's lives.
• We expect our cash, cash equivalents, and marketable securities will be sufficient to fund our operations for at least the next twelve months from the issuance date of these condensed consolidated financial statements based on current operating plans and financial forecasts.

Industry Context

The biopharmaceutical industry is highly competitive, with companies constantly seeking to develop and commercialize new medicines. Theravance Biopharma's YUPELRI competes in the COPD market, primarily against short-acting nebulized bronchodilators, but also faces new entrants like Verona Pharma's ensifentrine and Sanofi/Regeneron's Dupixent. Ampreloxetine, if approved, would enter the nOH market, currently dominated by generic droxidopa and midodrine, positioning itself as a potential first-in-class therapy for MSA patients. The strategic sale of TRELEGY royalties reflects a broader industry trend of companies monetizing non-core assets to strengthen balance sheets and focus on pipeline development.

Comparison to Industry Standards

• YUPELRI competes predominately with short-acting nebulized bronchodilators that are dosed three to four times per day, offering a once-daily advantage.
• Verona Pharma plc's ensifentrine, a selective inhaled dual inhibitor of PDE3 and PDE4, launched in the US in June 2024 as a maintenance treatment for adults with COPD, representing a new competitive therapy.
• Sanofi and Regeneron Pharmaceutical, Inc.'s IL-4/IL-13 monoclonal antibody (mAb) Dupixent (dupilumab) recently received approval in the US for COPD maintenance treatment for patients with moderate-to-severe COPD, who are uncontrolled with current SOC triple therapy (LAMA + LABA + ICS) and have evidence of Type 2 inflammation and frequent exacerbation history, indicating a shift towards more targeted therapies.
• Ampreloxetine, if successfully developed and approved, would enter a market where generic droxidopa is currently the sole product approved for nOH patients and midodrine is approved for OH, potentially offering a differentiated treatment option for MSA patients.

Corporate Governance

Legal Proceedings

• Ongoing patent infringement suits against two generic companies and their affiliates regarding generic versions of YUPELRI, consolidated in the U.S. District Court for the District of New Jersey.
• Settled litigation with Accord Healthcare, Inc.; Eugia Pharma Specialties Ltd.; Lupin Pharmaceuticals, Inc.; Orbicular Pharmaceutical Technologies Private Limited; Qilu Pharmaceuticals Co., Ltd.; and Teva Pharmaceuticals, Inc., granting them royalty-free licenses to manufacture and market generic YUPELRI in the US on or after April 23, 2039.
• FDA stay of approval through May 2026 has been imposed on generic companies' ANDAs pending any adverse court decision.
• Additional patent infringement suits were filed in August 2023, January 2024, August 2024, and May 2025 based on newly-issued patents covering YUPELRI, with expiration dates ranging from 2026 to August 2039.

Related Party Transactions

• Collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI, with profit and loss sharing (65% Viatris; 35% Theravance Biopharma) in the US and tiered royalties outside the US.
• Agreement with Royalty Pharma Investments for up to $40.0 million investment in ampreloxetine development in exchange for unsecured low single-digit royalties (2.5% up to $500M, 4.5% over $500M on annual global net sales).
• Sale of remaining royalty interest in TRELEGY to GSK for a one-time upfront payment of $225.0 million, while retaining the right to receive remaining potential $150.0 million in Milestone Payments from Royalty Pharma.

Stakeholder Impact

• Shareholders: Significant increase in cash and net income, potential for further shareholder value unlock through strategic review, but also risks of stock price volatility and dilution from future capital raises.
• Employees: Headcount reductions in 2021 and 2023 may make retention challenging, but continued pipeline development offers future opportunities.
• Customers/Patients: Continued commercialization of YUPELRI for COPD patients, and potential future availability of Ampreloxetine for nOH in MSA patients.
• Collaboration Partners (Viatris, GSK, Royalty Pharma): Ongoing and evolving relationships impact revenue streams and development efforts.
• Creditors: No long-term debt, strong cash position reduces immediate credit risk.

Next Steps

• Complete final patient enrollment in the Ampreloxetine Phase 3 CYPRESS study by late summer 2025.
• Anticipate top-line data for the Ampreloxetine Phase 3 CYPRESS study approximately six months after final patient enrollment.
• Continue to evaluate strategic alternatives to further enhance shareholder value through the Strategic Review Committee.
• Potentially receive remaining $150.0 million in Milestone Payments from Royalty Pharma based on TRELEGY global net sales thresholds in 2025 and 2026.
• Continue to assess the impact of the One Big Beautiful Bill Act (OBBBA) on consolidated financial statements and disclosures.

Key Dates

Recommendation

The company's financial health has dramatically improved, marked by a substantial net income and a significant increase in cash and marketable securities, largely due to the strategic monetization of TRELEGY royalties. This provides robust liquidity and financial flexibility. YUPELRI continues to demonstrate solid commercial performance with growing sales and long-term patent protection secured through recent settlements. The Ampreloxetine program, a wholly-owned asset with Orphan Drug Designation, is advancing towards a critical Phase 3 data readout, representing a major near-term catalyst. The ongoing strategic review committee signals a proactive approach to maximizing shareholder value. These factors, combined with a strong balance sheet and pipeline progress, position the company for potential significant upside.

Keywords

Biopharmaceutical, COPD, nOH, YUPELRI, Ampreloxetine, TRELEGY, SEC filing, 10-Q, financial results, drug development, patent litigation, royalties, healthcare, biotech, pharma